Benjamin H. Pensak

In his transactional work, Ben handles arrangements related to discovery, development, manufacture and supply, marketing, and outsourcing for life sciences companies and other innovative and developed technology companies. He also works with research organizations and institutions. Recognized by Chambers USA, Ben is hailed as having “an extremely high legal and life sciences IQ . . . . He is quick on his feet and is an excellent technical drafter.”

While earning his undergraduate degree in religion, Ben conducted a range of microbiology research focused primarily on gene therapy.

• Eli Lilly in its in-license with Chugai Pharmaceutical Co. Ltd. for OWL833, an oral, non-peptidic GLP-1 receptor agonist for the treatment of Type 2 diabetes; in-license and collaboration agreement with, and equity investment in, Sigilon Therapeutics related to the development of encapsulated cell therapies for the potential treatment of type 1 diabetes; in-license and collaboration agreement with, and equity investment in, CureVac AG related to the development and commercialization of cancer vaccine products based on CureVac's proprietary RNActive technology that targets tumor neoantigens; in-license agreement with Nektar Therapeutics to develop and commercialize NKTR-358, an IL-2 targeting drug designed to treat autoimmune diseases; out-license agreement with, and equity investment in, Ignyta, related to taladegib, an orally available, hedgehog/smoothened inhibitor; development and commercialization agreement with AstraZeneca related to BACE-inhibiting molecules; development and in-license agreement with Immunocore related to Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology; out-license agreement with Sanofi for the potential Rx-to-OTC switch of Cialis®; and co-development and co-commercialization agreement with Pfizer relating to tanezumab and other hNGF antibodies for the treatment of pain
• Xencor in its research and license agreement with Genentech to develop and commercialize IL-15 cytokine therapeutics; collaboration and out-license agreement with Novartis related to the development and commercialization of therapeutics based on Xencor’s bispecific antibody technology or XmAb® Fc technologies; out-license agreement with Amgen to Xencor’s XmAb® technologies for use in cancer immunotherapy and inflammation; and discovery and out-license agreement with Novo Nordisk to jointly discover novel biologic drug candidates combining multiple Xencor XmAb® technologies
• Gilead in its collaboration agreement with Scholar Rock Holding for the development and commercialization of Scholar Rock’s novel therapies for fibrotic diseases targeting latent TGF-beta1
• Merck in its in-license and collaboration agreement with NGM Biopharmaceuticals for a wide range of preclinical biologics; agreement to sell its consumer care business to Bayer; and co-promotion agreement with Taiho Pharmaceutical Co. Ltd. in Japan for pembrolizumab
• MEI Pharma in its out-license agreement with Kyowa Hakko Kirin for the development and commercialization in Japan of MEI-401, an oral inhibitor of PI3K delta; in-license agreement with Presage Biosciences for voruciclib, an oral and selective cyclin-dependent kinase inhibitor; and out-license agreement with Helsinn Group for the development and commercialization of pracinostat, an oral histone deacetylase inhibitor
• Regeneron Pharmaceuticals in its in-licensing and collaboration agreement with Intellia Therapeutics to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development
• Innovent Biologics in its co-development and co-commercialization agreement with Hanmi Pharmaceutical related to a bispecific antibody to be constructed using intellectual property contributions from both Hanmi and Innovent and enabling immunotherapy and targeted therapy at the same time; and development and in-license agreement with EpimAb Biotherapeutics for the development of bispecific antibodies using EpimAb’s Fabs-In-Tandem Immunoglobulin platform